Defining Frontline Treatment Considerations in Advanced Urothelial Carcinoma

Amit Mehta, MD, outlines the common toxicities encountered with immunotherapy-containing regimens in urothelial cancer and strategies to mitigate them.

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

Amit Mehta, MD, discusses the landscape of metastatic urothelial carcinoma, including data updates as well as treatment selection and safety considerations.

David J. Benjamin, MD, expands on real-world studies to help contextualize clinical trial data and inform treatment decisions in urothelial cancer.

David J. Benjamin, MD, discusses how he uses real-world data to supplement clinical trial results in urothelial carcinoma.

Chandler Park, MD, FACP, discusses optimal clinical scenarios for the use of the 3 approved first-line treatment options for patients with bladder cancer.

Dr Park discusses the core regimens in the current frontline bladder cancer treatment paradigm and ways that this paradigm is expected to evolve.

Chandler Park, MD, discusses key factors that facilitate decisions between the available frontline treatment regimens for patients with bladder cancer.